Citations

Clear

13603 citation(s) found for "_, _".

Letter to the Editor: Reply to “Population Screening for Cirrhosis” by Thiele et al, describing the Florida Healthy Liver Program
Ryland, Kristen, Harnois, Denise M. , Strong, Cyneetha, Whiddon, George, Mulrooney, Christopher, Littles, Alma B., Toskich, Beau , Ryland, Kristen L, Garza‐Ramos, Cynthia De la , Patel, Tushar , Mulrooney, Christopher

Mayo Clinic

Hepatology Communications | June 9, 2025 | Volume: 9 | Issue: 7 | Pages: No page available

10.1097/hc9.0000000000000713 | PMID 40489755 Get It

Knowledge, attitude, and perception of Pakistani women regarding breast cancer and mammography screening: A cross-sectional study
Rafay, Abdul , Ain, Hafiza Qurat Ul , Tahir, Muhammad Junaid , Saeed, Abdullah, Hanan, Abdul , Hassan, Zair , Ahmed, Khabab Abbasher Hussien Mohamed , Abbasher Hussien Mohamed Ahmed, Khabab , Asghar, Muhammad Sohaib , Mehmood, Qasim , Yousaf, Zohaib

Mayo Clinic

Medicine | June 9, 2025 | Volume: 104 | Issue: 23 | Pages: e42806

10.1097/md.0000000000042806 | PMID 40489872 Get It

Breast cancer is one of the most common cancers in females. In low- and middle-income countries like Pakistan, reported incidence and prevalence remain unreliable. The aim was to evaluate Pakistani women’s knowledge, attitude, and perception of breast cancer. This cross-sectional study was conducted among Pakistani women from Punjab, Pakistan. A self-administered online questionnaire was formulated to collect data from the participants from September 24, 2022, to October 24, 2022. The questionnaire included sociodemographic data, knowledge questions regarding breast cancer risk factors, knowledge questions about symptoms of breast cancer, and questions assessing the participants’ attitudes toward mammography screening. For knowledge questions, a score of more than 7 out of 13 was considered good knowledge. For attitude questions, regression analysis was done and a score of more than 5 out of 11 was considered a positive attitude. Data was analyzed using SPSS version 25 (Chicago). 796 women participated in this study. Out of 796 participants, 543 (68.2%) were between 20 and 30 years of age, and 43 (5.4%) were more than 40 years old. The level of knowledge regarding breast cancer risk factors was suboptimal. 523 (65.7%) of the participants thought that breast cancer risk increases with advancing age and 218 (27.4%) thought that early menarche increases the risk of developing breast cancer. 471 (59.2%) mentioned that mammography is an effective tool for detecting breast cancer, and 30 (3.8%) thought that there is a cure for breast cancer. According to regression analysis, higher education, higher monthly household income, and married marital status were significantly associated with good knowledge related to breast cancer. Although most of the population is aware of breast cancer’s risk factors and symptoms, they avoid screening such as mammography. Public awareness projects could help increase women’s knowledge of breast cancer signs, symptoms, and screening.
Monitoring Inflammatory Bowel Disease Activity: When, How, and Why
Gaidos, Jill , Hashash, Jana G.

Mayo Clinic

American Journal of Gastroenterology | June 9, 2025 | Volume: 120 | Issue: 8 | Pages: 1732-1741

10.14309/ajg.0000000000003582 | PMID 40488637 Get It

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, are disorders caused by inflammation in the gastrointestinal tract leading to a wide variety of symptoms. The presence of symptoms may not always correlate with active intestinal inflammation, and the lack of symptoms does not always indicate control of inflammation. Owing to the variable correlation between clinical symptoms and active intestinal inflammation, the targets for IBD management have been updated to include objective measures of inflammation to complement clinical end points. In addition to clinical remission, these targets include improvements in biochemical markers and endoscopic measures to objectively measure and monitor disease remission. In this review, we will discuss the different strategies for assessing disease activity and the timing of evaluation for each treatment target for outpatient IBD care. We will also highlight the role of radiographic assessment with a focus on intestinal ultrasound for monitoring these treatment end points.
Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma
Campian, Jian , Grossman, Stuart A. , Kask, Angela Shaulov , Kosydar, Samuel , Piotrowski, Anna F. , Tang, Justin , Chheda, Milan G. , Schullery, Dan, Desideri, Serena , Danda, Neeraja , Ferrando-Martinez, Sara , Lee, Byung Ha , Fling, Steven P. , Ye, Xiaobu , Grossman, Stuart A , Kosydar, Samuel R , Strowd, Roy E. , DiPersio, John F. , Schullery, Dan, D’Amico, Leonard

Mayo Clinic

Neuro-Oncology Advances | June 7, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf117 | PMID 40703805 Get It

Abstract Background High-grade gliomas (HGG) have a poor prognosis despite aggressive treatment. Severe, persistent lymphopenia occurring in HGG patients after concurrent chemoradiation is associated with worse survival. NT-I7, a long-acting interleukin-7 analog, has been shown to increase CD4 and CD8 counts in healthy, septic, and HIV-positive adults. This multi-institutional, NCI-funded dose-escalation trial is the first to evaluate NT-I7 safety and activity in HGG patients with severe treatment-related lymphopenia (TRL) and the effect of co-administered glucocorticoids. Methods Eligible HGG patients had CD4 counts <300 cells/mm3 after 5 weeks of standard chemoradiation and were receiving either ≤0.75 or ≥4 mg/day of dexamethasone. Patients received a single intramuscular dose of NT-I7 (60 or 360 µg/kg) post-chemoradiation, followed by safety evaluation and multi-parameter, longitudinal monitoring of lymphocyte populations and immunologic function. Results NT-I7 was well tolerated in all 12 patients (median age 64; median CD4 count 161 cells/mm³) before the study closed prematurely. Absolute lymphocyte counts doubled in 83% (10/12; 95% CI: 51.6%-97.9%) of patients, and CD4 counts doubled in 42% (5/12; 95% CI: 15.2%-72.3%) of patients. Glucocorticoid use did not significantly affect CD4 or lymphocyte increases. Correlative immune profiling revealed increased Ki67 expression in CD4 (P < .005) and CD8 (P < .05) after one week, along with the expansion of CD4 and CD8 T-cell subsets and CD56 + natural killer cells. Conclusions NT-I7 is well tolerated and effectively increases lymphocyte and CD4 counts in severe TRL patients, regardless of glucocorticoid use, suggesting its potential to mitigate TRL and improve outcomes in HGG.
Stereotactic radiosurgery versus observation for intracranial low-grade dural arteriovenous fistulas
Becerril‐Gaitan, Andrea , Peesh, Pedram , Liu, Collin, Lee, Cheng-chia, Niranjan, Ajay , Lunsford, L. Dade , Wei, Zhishuo , Hoang, A, Sheehan, Jason P. , Dayawansa, Sam , Samanci, Yavuz, Starke, Robert M. , Ikeda, Go , Kano, Hideyuki , Wang, Qian , Welch, Babu G. , O’Con, Jennifer, Lanzino, Guiseppe, Brinjikji, Waleed , Hayakawa, M. , Gross, Bradley A. , Albuquerque, Felipe C , Lawton, Michael T., Kim, Louis J. , Alaraj, Ali , Winkler, Ethan A. , Chalouhi, Nohra , Bulters, Diederik , Durnford, Andrew , Satomi, Junichiro, Tada, Yoshiteru , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Laurent, Dimitri , Bahmani, Brigette, Zipfel, Gregory J. , Samancı, Yavuz , Tripathi, Manjul , Welch, Babu , Du, Rose , Lai, Rosalind , Gross, Bradley , Levitt, Michael R , Alaraj, Ali , van DijK, J Marc C , Osbun, Joshua W , Bulters, Diederik O , Yang, Huai‐Che , Peker, Selçuk , Abdelsalam, Ahmed , Kondziolka, Douglas , Bernstein, Kenneth, Ming, Ying, Liščák, Roman , May, Jaromír , Li, Wen , O’Con, Jennifer, Amin-Hanjani, Sepideh , Nguyen, Quang, Samaniego, Edgar A , Lai, Pui Man Rosalind , Derdeyn, Colin P. , Abla, Adib A. , Lawton, Michael T. , Kim, Louis J. , Levitt, Michael R. , Hoh, Brian L. , Chen, Ching‐Jen

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | June 6, 2025 | Volume: 96 | Issue: 11 | Pages: 1117-1125

10.1136/jnnp-2024-335675 | PMID 40480804 Get It

Background Given the low haemorrhagic risk of intracranial low-grade dural arteriovenous fistulas (dAVFs), the benefits of routine intervention remain controversial. This study compares patient outcomes treated with stereotactic radiosurgery (SRS) versus conservative management. Method Multicentre retrospective analysis of the Consortium for Dural Arteriovenous Fistula Outcomes Research and the International Radiosurgery Research Foundation data. Inclusion criteria were (1) intracranial low-grade dAVF diagnosed by catheter-based angiography, (2) no prior dAVF-related haemorrhage and (3) management with upfront SRS (intervention group) or conservative management (observation group). The primary outcome was symptomatic improvement. Secondary outcomes included dAVF obliteration, up-conversion, haemorrhage, improvement and favourable modified Rankin Scale (mRS) at follow-up. Results 304 patients with a mean age of 56 years (SD 13.5) and a follow-up of 46.7 months (SD 45.5) were included. 135 (44.4%) were managed conservatively and 169 (55.6%) had upfront SRS. Compared with the observation group, symptomatic and mRS Score improvement (≥1-point decrease in baseline score) was more likely in the intervention group (95.1% vs 58.5%; OR=13.75 (5.61–33.69) and 37.0% vs 24.0%; OR=1.85 (1.09–3.15), respectively). These findings remained significant after multiple imputation and propensity score matching. Remaining outcomes were similar between groups. The all-cause mortality rate was 5.4% (n=16), unrelated to the dAVF or treatment. Five (3.0%) SRS-related complications were reported and resolved during the follow-up period. Conclusions SRS was associated with increased symptomatic and mRS Score improvement for low-grade dAVFs compared with conservative management. SRS had a low complication risk and did not appear to alter dAVF obliteration or haemorrhage. Future prospective trials on SRS as a first-line intervention for symptomatic low-grade dAVFs should be considered.
Bone Marrow Aspirate Concentrate May Decrease Reoperation in Osteochondral Allograft Transplantation: A Prospective, Randomized, Double‐Blind Investigation
Yanke, Adam B. , Dandu, Navya , Bodendorfer, Blake M. , Trasolini, Nicholas A. , Hevesi, Mario , Elias, Tristan J. , Haneberg, Erik , Darwish, Reem , Forsythe, Brian , Cole, Brian J. , Hevesi, Mario , Forsythe, Brian , Haneberg, Erik C , Zavras, Athan G.

Mayo Clinic

Arthroscopy | June 5, 2025 | Volume: 41 | Issue: 11 | Pages: 4664

10.1016/j.arthro.2025.05.024 | PMID 40482979 Get It

Purpose To perform a prospective, double‐blind, randomized controlled trial to assess differences in integration and patient‐reported outcomes metrics (PROMs) of osteochondral allograft transplantation with and without bone marrow aspirate concentrate (BMAC) augmentation. Methods Patients (n = 36) undergoing osteochondral allograft transplantation of the knee were consented and enrolled in this prospective study. They were randomized to either iliac crest BMAC or sham incision groups and blinded to their allocation. Computerized tomography (CT) scans of the knee were obtained at 6 months postoperatively after the index transplantation and graded by the semiquantitative assessment CT osteochondral allograft system. PROMs, including the International Knee Documentation Committee and Knee injury and Osteoarthritis Outcome Score–Joint Replacement, were obtained at 6 months, 1 year, and 2 years postoperatively. Results On 6‐month postoperative CT scans, patients receiving BMAC‐treated grafts were more likely to have small cystic changes ( P = .01), with an associated trend toward reduction in large cyst formation ( P = .06), but equal osseous integration, graft signal density, and presence of discernible clefts and intra‐articular fragments. The BMAC group was less likely to undergo subsequent surgery for graft debridement or revision (5.3% vs 35.3%; P = .02). There were no significant differences in PROMs between the 2 groups preoperatively or postoperatively at 6 months, 1 year, or 2 years. Patients receiving BMAC trended toward a higher rate of achievement of Knee Documentation Committee and Knee injury and Osteoarthritis Outcome Score–Joint Replacement minimal clinically important difference (88% vs 55%; P = .076). Conclusions Patients receiving BMAC‐treated grafts were more likely to have small cystic changes and were less likely to undergo subsequent surgery for persistent or new symptoms after the index procedure. No difference in postoperative PROMs was shown at the 6‐month, 1‐year, and 2‐year follow‐ups between the 2 groups. Level of Evidence Level I, prospective, randomized controlled trial.
The 6 Pillars of Lifestyle Medicine and Prevalence of Cardiovascular and Cardiometabolic Diseases in Brazil: A Cross-Sectional, Population-Based Study Involving 88,531 Adults
Oliveira, Arão Belitardo , Woldeamanuel, Yohannes W. , Pereira, Larissa Karen, Oliveira, Lucas Alves de Brito , Peres, Mário Fernando Prieto , Goulart, Alessandra C. , Woldeamanuel, Yohannes Woubishet , Pereira, Larissa Karen , Rozen, Todd D. , Mota, Jorge Augusto Pinto Silva

Mayo Clinic

American Journal of Lifestyle Medicine | June 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15598276251348170 | PMID 40485745 Get It

Objective: We aimed to estimate the prevalence of cardiovascular diseases (CVDs) and cardiometabolic diseases (CMB) in Brazil, and their relationship with a healthy lifestyle score based on the six pillars of lifestyle medicine proposed by the American College of Lifestyle Medicine. Methods: Data were derived from the 2019 Brazilian National Health Survey, a nationwide cross-sectional study. The prevalence of CVDs/CMB was based on medical-endorsed, self-reported diagnoses and weighted for sample strata. A healthy lifestyle score (0-14 points; the higher the score, the better) incorporates physical activity, diet, sleep, mental health, risky substance use, and social connections. Results: Among 88,531 adults included in the analysis (mean age: 47.1 years; 52.9% female), the weighted prevalence of CVDs/CMB ranged from 1.9% (stroke) to 25.9% (hypertension). Weighted Poisson regression models, adjusted for age, sex, socioeconomic status, and geographic disparities, showed an inverse linear relationship between lifestyle score and CVDs/CMB prevalence. Participants in the highest lifestyle score quartile exhibited lower prevalence for heart diseases [0.48 (95% CI: 0.43, 0.53)], stroke [0.35 (95% CI: 0.29, 0.43)], hypertension [0.85 (95% CI: 0.80, 0.90)], diabetes [0.80 (95% CI: 0.70, 0.91)], dyslipidemia [0.73 (95% CI: 0.66, 0.80)], and obesity [0.81 (95% CI: 0.74, 0.88)], compared to the lowest quartile ( P < 0.001 for all). Conclusions: Higher scores on the six pillars of lifestyle medicine are associated with a lower prevalence of major CVDs/CMB in Brazil.
Risk factors, impact, and healthcare use related to initial suicide attempts: comprehensive analysis of Swedish population
Hu, Kejia , Dung, Nguyen Thi Thuy , Borges, Karen, Kuja‐Halkola, Ralf , Butwicka, Agnieszka , Brikell, Isabell , Crowley, James J, D’Onofrio, Brian M. , Larsson, Henrik , Lu, Yi , Crowley, James J. , Nguyen, Thuy-Dung , Rück, Christian , Hu, Kejia , Kuja-Halkola, Ralf , Lu, Yi , Brikell, Isabell , Crowley, James J, Chang, Zheng, Lichtenstein, Paul , Bulik, Cynthia Marie , Sullivan, Patrick F. , Fang, Fang , Crowley, James J.

Mayo Clinic

BMJ Medicine | June 5, 2025 | Volume: 4 | Issue: 1 | Pages: e001129

10.1136/bmjmed-2024-001129 | PMID 40510927 Get It

Objective To provide a comprehensive analysis of initial suicide attempts, covering incidence, risk factors, outcomes, and healthcare use in the month before and the month after the attempts. Design Comprehensive analysis of the Swedish population that included three designs: a retrospective cohort study to investigate incidence and healthcare use, a nested case-control study to investigate risk factors, and a matched cohort study to examine subsequent suicide attempts and mortality. Setting Comprehensive Swedish national registers that include patient diagnoses from hospitals and specialist outpatient care, and cause of death information updated to the end of 2019. Participants 3.7 million people born in Sweden in 1963-98 and followed from age 10 to 57 years. Main outcome measure First lifetime suicide attempt identified in patient and death registers using ICD (international classification of diseases) codes for intentional self-harm, any self-harm with lethal methods or requiring hospital admission, or any self-harm resulting in death. Results The lifetime risk of an initial suicide attempt in the study population was 4.6%, with greater risk in females and highest risk between ages 18 and 24. One in 10 families in Sweden had at least one family member who attempted suicide. Overdose and poisoning were the most common methods. Previous psychiatric disorders, general medical diseases, and adverse life events were associated with increased risk of initial suicide attempt, while higher socioeconomic status was associated with decreased risk. People with an initial suicide attempt were at substantially increased risk of subsequent attempts (hazard ratio 23.4), death by suicide (16.4), and all cause mortality (7.3). At least 60% of those who made an initial suicide attempt had a healthcare contact in the month before the attempt. Conclusions This study provides comprehensive data on the incidence, risk factors, outcomes, and healthcare use of initial suicide attempts in the Swedish population, highlighting the need for systematic prevention efforts for people who have attempted suicide for the first time.
A phase 1 clinical trial shows safe, sustained, AAV-mediated expression of IL-1Ra in the human osteoarthritic knee joint
Vega, Rodolfo E. De la , Sellon, Jacob L. , Smith, Jay , Wisniewski, Stephen, Jurisson, Mary L. , Frick, Matthew A., Scrabeck, Tyson L., Block, Julie B., Mills, Candee J. , Pohlkamp, Zachary W., Coenen, Michael J., Hawse, Gresin P. , Abdul, Temilola Y. , Conaghan, Philip G. , Keravala, Annahita, Robbins, Paul D. , Ghivizzani, Steven C. , Evans, Christopher H. , De La Vega, Rodolfo E , Wisniewski, Stephen J, Conaghan, Philip , Chalberg, Thomas W , Robbins, Paul D , Ghivizzani, Steven C , Evans, Christopher H , Block, Julie B.

Mayo Clinic

Science Translational Medicine | June 4, 2025 | Volume: 17 | Issue: 801 | Pages: No page available

10.1126/scitranslmed.adu9804 | PMID 40465688 Get It

Osteoarthritis (OA) is a major global health problem with no disease-modifying therapies. Interleukin-1 (IL-1) is a critical cytokine associated with the pathophysiology of OA and can be inhibited by IL-1 receptor antagonist (IL-1Ra). Here, we tested the delivery of a gene therapeutic encoding the human IL-1Ra to the knee in a phase 1, open-label clinical trial that enrolled nine patients with radiographic knee OA. The IL-1Ra gene was delivered by a self-complementary (sc)–recombinant adeno-associated virus (rAAV) serotype 2.5 (sc-rAAV2.5IL-1Ra) by intra-articular injection into an index knee at one of three doses: low [1 × 10 11 viral genomes (vg)], mid (1 × 10 12 vg), or high (1 × 10 13 vg). The primary outcome was safety. There were no serious adverse events (AEs) related to sc-rAAV2.5IL-1Ra. Two AEs occurred that were possibly related to the vector. Both were effusions with increased pain and resolved with conservative treatment. sc-rAAV2.5IL-1Ra did not cause changes in vital signs, physical findings, or clinical laboratory measures. Less than 1% of the injected dose of sc-rAAV2.5IL-1Ra vg was detected in circulation after 1 day and was cleared within a week. Titers of neutralizing antibodies to AAV2.5 rose in serum and synovial fluid. In all cases, IL-1Ra concentration increased in the synovial fluid, and IL-1Ra concentrations remained elevated after 1 year. Baseline pain and function scores improved during the study. Therefore, we found that intra-articular gene therapy with sc-rAAV2.5IL-1Ra was safe. The sustained increase in local IL-1Ra in human knee joints supports the further clinical examination of this therapy to provide therapeutic benefit in OA.
Hyperinsulinemia-induced upregulation of adipocyte TPH2 contributes to peripheral serotonin production, metabolic dysfunction, and obesity
Park, Brian I., Reeves, Andrew R., Wilson, Robin A. , Fernandes, Sophia C., Buhman, Kimberly K. , Lytle, Kelli A. , Jensen, Michael D. , Greenberg, Andrew S. , Park, Brian I., Reeves, Andrew R., Zhu, Ying , Fernandes, Sophia C., Jensen, Michael

Mayo Clinic

Journal of Clinical Investigation | June 4, 2025 | Volume: 135 | Issue: 14 | Pages: No page available

10.1172/jci190765 | PMID 40455408 Get It

Tryptophan hydroxylase (TPH) is a rate-limiting enzyme for serotonin or 5-hydroxytryptamine (5-HT) synthesis. Previously, adipocyte TPH1 has been linked to increased adipose 5-HT, reduced brown adipose tissue (BAT) thermogenesis, and obesity. However, the role of TPH2, a neural isoform highly expressed in obese adipose tissue, is unknown. Here, we report that adipose tissue expression of TPH2 is dramatically elevated in mice with diet-induced obesity (DIO) and ob/ob mice, as well as in obese humans. In mice fed a high-fat diet, adipocyte TPH2 deficiency improved DIO-induced metabolic complications, enhanced BAT thermogenesis, and increased intestinal energy-harvesting efficiency without affecting adiposity. Conversely, TPH2 overexpression in epididymal adipocytes of chow-fed mice raised adipose and plasma 5-HT levels, suppressed BAT thermogenesis, and exacerbated obesity and metabolic dysfunction. We found that obesity-induced hyperinsulinemia upregulated adipocyte TPH2 expression via activation of mechanistic target of rapamycin complex 1 and SREBP1. In humans, TPH2 mRNA levels in subcutaneous adipose tissue, but not those of TPH1 , are positively correlated with fasting plasma insulin concentrations. In summary, our study demonstrates that obesity-associated increases in adipocyte TPH2 can regulate distal tissue physiology and energy metabolism, suggesting that TPH2 could be a potential therapeutic target for obesity and its associated complications.